Establishment of highly invasive pancreatic cancer cell lines and the expression of IL-32

被引:13
|
作者
Takagi, Kohji [1 ]
Imura, Johji [1 ]
Shimomura, Akiko [1 ]
Noguchi, Akira [1 ]
Minamisaka, Takashi [1 ]
Tanaka, Shinichi [1 ]
Nishida, Takeshi [1 ]
Hatta, Hideki [1 ]
Nakajima, Takahiko [1 ]
机构
[1] Univ Toyama, Acad Assembly, Fac Med, Dept Diagnost Pathol, 2630 Sugitani, Toyama, Toyama 9300194, Japan
基金
日本学术振兴会;
关键词
pancreatic cancer cell; invasion; comprehensive genomic analysis; cell culture; interleukin-32; INTERLEUKIN-32; PROGRESSION; GENE;
D O I
10.3892/ol.2020.11825
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Compared to tumors of other organs, pancreatic cancer is highly aggressive; with one of its biological features being that, despite a prominent fibrotic stroma, there is remarkable infiltration of tumor cells. This characteristic is considered to be the main reason for the poor prognosis of patients with pancreatic cancer. Therefore, in order to elucidate the factors that contribute to this high invasiveness, a selective invasion method was used to establish four highly invasive subclones from six human pancreatic cancer cell lines. The results demonstrated that two cell lines did not exhibit enhanced invasiveness. Microarray analysis revealed that, in the highly invasive cell lines, several genes were expressed at high levels, compared with the original cell lines. These highly expressed genes were recognized only in highly invasive cells. Among them,IL-32was most strongly upregulated in the highly invasive cells, compared with cells with a low invasive potential, as well as the original cells. RT-qPCR and western blot analysis confirmed the high levels of expression of IL-32 in highly invasive cells at the RNA and protein levels. In addition, immunohistochemical analysis of resected surgical materials revealed that the tumor cells expressed IL-32 and, in particular, many IL-32 positive cells were seen at the invasive front of the tumor tissue. IL-32 is a cytokine that is widely involved in the development of cancer and has recently received considerable attention. This cytokine has multiple splice variants and shows a wide variety of behaviors, depending on the tumor type and primary organ. Although some hypotheses have been proposed to explain the activity of IL-32, a unified view has not been agreed. In the present study, through the establishment of highly invasive cells from pancreatic cancer and a comprehensive gene analysis, it is suggested that IL-32 may serve an important role as a molecule involved in the invasiveness of this neoplasm.
引用
收藏
页码:2888 / 2896
页数:9
相关论文
共 50 条
  • [21] IL-32 expression associated with lymph vessel invasion in intestinal type of gastric cancer
    Pavlovic, Mladen
    Jurisevic, Milena
    Gajovic, Nevena
    Mitrovic, Slobodanka
    Jovanovic, Milan
    Radosavljevic, Gordana
    Pantic, Jelena
    Radovanovic, Dragce
    Arsenijevic, Nebojsa
    Jovanovic, Ivan
    VOJNOSANITETSKI PREGLED, 2020, 77 (08) : 816 - 825
  • [22] Unique expression of a small IL-32 protein in the Jurkat leukemic T cell line
    Ko, Na-Young
    Chang, Sung-Ho
    Lee, Jun-Ho
    Kim, Nam-Wook
    Kim, Young-Mi
    Choi, Wahn-Soo
    Choi, Ji-Da
    Bae, Su-Young
    Hong, Jae-Woo
    Jaekal, Jun
    Azam, Tania
    Her, Erk
    Kim, Soo-Hyun
    CYTOKINE, 2008, 42 (01) : 121 - 127
  • [23] Polymorphisms and expression of IL-32: impact on genetic susceptibility and clinical outcome of lung cancer
    Wang, Yanwen
    Yang, Yongfeng
    Zhu, Yihan
    Li, Li
    Chen, Fei
    Zhang, Li
    BIOMARKERS, 2017, 22 (02) : 165 - 170
  • [24] Establishment and characterization of two cell lines of anaplastic pancreatic cancer
    Miura, Kotaro
    Kimura, Kenjiro
    Amano, Ryosuke
    Yamazoe, Sadaaki
    Hirata, Keiichiro
    Shibutani, Masatsune
    Sakurai, Katsunobu
    Nagahara, Hisashi
    Toyokawa, Takahiro
    Kubo, Naoshi
    Tanaka, Hiroaki
    Muguruma, Kazuya
    Otani, Hiroshi
    Yashiro, Masakazu
    Maeda, Kiyoshi
    Ohira, Masaichi
    Hirakawa, Kosei
    CANCER RESEARCH, 2014, 74 (19)
  • [25] Single-cell transcriptomics reveals prominent expression of IL-14, IL-18, and IL-32 in psoriasis
    Frost, Bennet
    Schmidt, Maria
    Klein, Benjamin
    Loeffler-Wirth, Henry
    Krohn, Knuth
    Reidenbach, Timo
    Binder, Hans
    Stubenvoll, Antonia
    Simon, Jan C.
    Saalbach, Anja
    Kunz, Manfred
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2023,
  • [26] The Role of IL-32 in Cutaneous T-Cell Lymphoma
    Suga, Hiraku
    Sugaya, Makoto
    Miyagaki, Tomomitsu
    Kawaguchi, Makiko
    Fujita, Hideki
    Asano, Yoshihide
    Tada, Yayoi
    Kadono, Takafumi
    Sato, Shinichi
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2014, 134 (05) : 1428 - 1435
  • [27] Establishment of novel human pancreatic cancer cell lines (KMP series).
    Kato, M
    Shimada, Y
    Tanaka, H
    Doi, R
    Ohshio, G
    Hosotani, R
    Imamura, M
    GASTROENTEROLOGY, 1996, 110 (04) : A540 - A540
  • [28] Expression of highly polysialylated neural cell adhesion molecule in pancreatic cancer neural invasive lesion
    Kameda, K
    Shimada, H
    Ishikawa, T
    Takimoto, A
    Momiyama, N
    Hasegawa, S
    Misuta, K
    Nakano, A
    Nagashima, Y
    Ichikawa, Y
    CANCER LETTERS, 1999, 137 (02) : 201 - 207
  • [29] Interplay between thyroid cancer cells and macrophages: effects on IL-32 mediated cell death and thyroid cancer cell migration
    Yvette J. E. Sloot
    Katrin Rabold
    Thomas Ulas
    Dennis M. De Graaf
    Bas Heinhuis
    Kristian Händler
    Joachim L. Schultze
    Mihai G. Netea
    Johannes W. A. Smit
    Leo A. B. Joosten
    Romana T. Netea-Maier
    Cellular Oncology, 2019, 42 : 691 - 703
  • [30] Interplay between thyroid cancer cells and macrophages: effects on IL-32 mediated cell death and thyroid cancer cell migration
    Sloot, Yvette J. E.
    Rabold, Katrin
    Ulas, Thomas
    De Graaf, Dennis M.
    Heinhuis, Bas
    Haendler, Kristian
    Schultze, Joachim L.
    Netea, Mihai G.
    Smit, Johannes W. A.
    Joosten, Leo A. B.
    Netea-Maier, Romana T.
    CELLULAR ONCOLOGY, 2019, 42 (05) : 691 - 703